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The function of the stress-responsive N-myc downstream-regulated gene 2 (NDRG2) in the control of
myoblast growth, and the amino acids contributing to its function, are not well characterized. Here,
we investigated the effect of increased NDRG2 levels on the proliferation, differentiation and apop-
tosis in skeletal muscle cells under basal and stress conditions. NDRG2 overexpression increased
C2C12 myoblast proliferation and the expression of positive cell cycle regulators, cdk2, cyclin B
and cyclin D, and phosphorylation of Rb, while the serine/threonine-deficient NDRG2, 3A-NDRG2,
had less effect. The onset of differentiation was enhanced by NDRG2 as determined through the
myogenic regulatory factor expression profiles and myocyte fusion index. However, the overall level
of differentiation in myotubes was not different. While NDRG2 up-regulated caspase 3/7 activities
during differentiation, no increase in apoptosis was measured by TUNEL assay or through cleavage
of caspase 3 and PARP proteins. During H2O2 treatment to induce oxidative stress, NDRG2 helped
protect against the loss of proliferation and ER stress as measured by GRP78 expression with 3A-
NDRG2 displaying less protection. NDRG2 also attenuated apoptosis by reducing cleavage of PARP
and caspase 3 and expression of pro-apoptotic Bax while enhancing the pro-survival Bcl-2 and
Bcl-xL levels. In contrast, Mcl-1 was not altered, and NDRG2 did not protect against palmitate-
induced lipotoxicity. Our findings show that NDRG2 overexpression increases myoblast proliferation
and caspase 3/7 activities without increasing overall differentiation. Furthermore, NDRG2 attenu-
ates H2O2-induced oxidative stress and specific serine and threonine amino acid residues appear
to contribute to its function in muscle cells.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The progression of dividing myoblasts to commence fusion into
multinucleated muscle cells is a tightly coordinated process involv-
ing cell cycle regulators interacting with myogenic regulatoryfactors (MRFs) as well as apoptosis. The MRFs, myogenic factor 5
(Myf5) and myogenic differentiation (MyoD) are required for nor-
mal myoblast proliferation and are regulated by positive cell cycle
regulatory complexes such as cyclin E-cyclin-dependent kinase 2
(Cdk2) [1] and cyclin B-Cdk1 [2]. The activation of Cdks and cyclins
in turn phosphorylate the tumor suppressor retinoblastoma (Rb)
protein releasing its inhibitory effect on cell cycle progression
(reviewed in [3]). In addition, MyoD promotes the onset of cell cycle
arrest and commitment to differentiate through activation of the
cell cycle inhibitor p21 waf1/cip1 (p21) [4]. The MRF myogenin is
also responsible for cell cycle exiting and assists myoblasts to fuse
in conjunction with p21 to enter the post-mitotic state [5]. During
this process, a proportion of myoblasts undergo apoptosis that are
thought to enhance myoblast fusion [6], whereas p21 protects fus-
ing myocytes against apoptosis once they are committed to differ-
entiate, particularly during in vitro myogenesis [7]. During
differentiation, the activities of the pro-apoptotic enzymes caspase
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entiation [8,9] while the anti-apoptotic B cell leukemia/lymphoma
2 (Bcl-2) gene also contributes to skeletal muscle postnatal devel-
opment, particularly in fast twitch muscle fiber formation [10]. In
addition to normal apoptosis during myogenesis, apoptosis in
skeletal muscle may occur during disease conditions [11]. During
stress conditions, Bcl-2 members, such as the pro-apoptotic
Bcl-2-associated X protein (Bax), may help mediate apoptosis in
myotubes [11] as observed following palmitate (PA)-induced lipo-
toxicity [12]. However, our understanding of the molecular factors
controlling and coordinating muscle cell proliferation and differen-
tiation, in conjunction with apoptosis and increased caspase
activity, is far from complete and requires continued investigation.
The N-myc downstream-regulated gene 2 (NDRG2) is highly
expressed in skeletal muscle tissue both at the gene level [13]
and as a phosphoprotein [14]. NDRG2 expression increases with
myoblast differentiation and contributes to muscle cell growth as
its knockdown attenuates C2C12 myoblast proliferation and differ-
entiation [15]. In addition, NDRG2 is considered a stress-response
molecule as its expression is induced under hypoxic conditions
[16,17] and radiation [17] in cancer cells, for example; and follow-
ing catabolic treatment in skeletal muscle cells [15]. Conversely,
anabolic factors including testosterone, insulin and insulin-like
growth factor suppress NDRG2 gene expression in muscle cells
[15]. The increased endogenous expression of NDRG2 could indi-
cate a natural protective response against stress effects. Indeed, a
loss of NDRG2 attenuated the protective effect of thymoma viral
proto-oncogene (Akt) overexpression in pancreatic beta cells fol-
lowing PA treatment [18], and reduced Bcl-2 levels in cervical can-
cer cells promoting their sensitivity to cisplatin treatment [19].
Furthermore, NDRG2 overexpression protected against radiation-
induced apoptosis and the up-regulation of Bax in Hela cells [17].
In contrast to these studies, the overexpression of NDRG2 is
reported to reduce the neuroprotective effect of sevoflurane pre-
treatment in astrocytes following oxygen–glucose deprivation
[20]. Currently, it is unclear as to whether enhanced levels of
NDRG2 will have an overall beneficial outcome during different
stress conditions or whether the benefit is cell-type specific. As
skeletal muscle cells are sensitive to multiple stress conditions
such as lipotoxicity [21] and oxidative stress through hydrogen
peroxide treatment [22], which is also linked to the activation of
endoplasmic reticulum (ER) stress [23], the effects of such stresses
in the presence of elevated NDRG2 will further our understanding
of NDRG2’s role in skeletal muscle function.
The specific protein regions contributing to the function of
NDRG2 are not well characterized. In skeletal muscle cells, previ-
ous studies have identified serine (Ser) and threonine (Thr) amino
acid-rich regions in the C-terminus of human and mouse NDRG2
[24,25]. These residues in mouse NDRG2, including the Ser332,
Thr348 and Ser350 amino acids, may be phosphorylated by insulin
and by Ser/Thr kinases including Akt and protein kinase C theta
(PKCh) [24,25], factors that affect myoblast proliferation, fusion
and myotube development [26–28]. Interestingly, PKCh’s phospho-
rylation of Ser332 reduces insulin’s ability to phosphorylate Thr348
[24] although the functional consequence of this for NDRG2 is
unknown. In cancer cells, Ser and Thr amino acids appear to con-
tribute, either individually or collectively, to NDRG2’s ability to
inhibit colon carcinoma cell proliferation [29] indicating that the
phosphorylation status of NDRG2 is important for its function.
Therefore, the aims of this study were to investigate the effect of
NDRG2 overexpression on proliferation, differentiation and apop-
tosis under both normal growth and stress-induced conditions in
C2C12 muscle cells. Furthermore, we determined whether the
combined removal of the Ser332, Thr348 and Ser350 residues, making
NDRG2 phospho-deficient, impacted the role of NDRG2 on these
processes.2. Materials and methods
2.1. Cell culture
Mouse C2C12 myoblasts (ATCC, Manassas, VA, USA) were cul-
tured in growth medium containing 25 mM glucose Dulbecco’s
Modified Eagle Medium (DMEM) and 10% fetal bovine serum
(FBS) (Life Technologies, Mulgrave, VIC, AUS) at 37 C in 5% CO2.
To differentiate cells, differentiation medium consisting of 2%
horse serum and 25 mM glucose DMEM was added when cells
were confluent and refreshed every 48 h. Platinum-E (Plat-E) cells
(Jomar Bioscience, Welland, SA, AUS) were used for the production
of retrovirus and were cultured in growth medium at 37 C in 5%
CO2. To induce oxidative stress, myoblasts were treated with
0.5 mM hydrogen peroxide (H2O2; Sigma–Aldrich, St. Louis, MO,
USA) in 10% FBS DMEM for 4 or 8 h. For lipotoxic treatments, PA
(Sigma–Aldrich, P0500) was dissolved in 100% ethanol and
conjugated for 1 h at 37 C with gentle rotation with 10% fatty
acid-free bovine serum albumin (FAF-BSA, Sigma–Aldrich) in
serum-free DMEM at a final concentration of 4.5 mM PA and
1.5 mM FAF-BSA (3:1 ratio). The equivalent amount of 100% ethanol
was added to 10% FAF-BSA/DMEM as a vehicle control treatment.
C2C12 myoblasts were treated with 0.5 mM PA conjugated with
FAF-BSA or with vehicle control for 8 or 16 h in 10% FBS DMEM.2.2. Protein stability study
The production of the FLAG-tagged wild type and phospho-
deficient mouse NDRG2 expression constructs, pCMV/SV-FLAG1-
NDRG2 and -3A-NDRG2, were described previously [24]. The
amino acids Ser332, Thr348 and Ser350 in the phospho-deficient form
of mouse NDRG2 (3A-NDRG2) had been replaced with alanine resi-
dues. C2C12 myoblasts plated at 8  104 cells/ml and 24 h later
plasmids were transiently transfected into Plat-E cells using
Lipofectamine 2000 transfection reagent (Life Technologies) and
OptiMem medium (Life Technologies) as recommended by the
manufacturer. Cells were treated with 10 lg/ml cycloheximide
for up to 24 h prior to harvesting of protein lysates.2.3. Retroviral infection
NDRG2 and 3A-NDRG2 were amplified from pCMV/SV-FLAG1
plasmids using primers: forward 50 AGTGAGATCTACCATGGCAGA
ACTTCAGGAGGT and reverse 50 GTTCGTCGACTCAACAGGAGACTTC
CATGG. The cDNAs were cloned into the SalI and BglII sites of the
pMSCV-IRES-hygromycin (pMIH) retroviral vector as previously
described [30] to generate wild type and phospho-deficient,
pMIH-WT-NDRG2 and pMIH-3A-NDRG2 plasmids, respectively.
For the production of the retroviruses, empty pMIH vector (vector),
pMIH-WT-NDRG2 (NDRG2) and pMIH-3A-NDRG2 (3A-NDRG2)
plasmids were transiently transfected into Plat-E cells plated at
4  105 cells/ml essentially as described before [15]. Virus was
allowed to accumulate in the media over 48 h prior to harvesting.
The supernatant containing each virus was centrifuged to remove
dead cells and then diluted 1:6 in growth medium containing
6 lg/ml polybrene (Sigma–Aldrich) before adding to C2C12 myo-
blasts plated at 1.8  104/ml 24 h earlier. Cells with virus media
were centrifuged at 1800 rpm for 45 min and left to incubate at
37 C in 5% CO2 for 5 h before being replaced with fresh growth
medium. The following day, cells were selected with 800 lg/ml
of hygromycin for 36 h prior to re-plating at 1.5  104/ml for all
assays. Cells were harvested across a time-course encompassing
both proliferating and differentiating myoblasts. Myoblasts were
analzsed during proliferation at two and three days (P2 and P3)
post-plating and then at day four (D0) when myoblasts were
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myoblasts were differentiated for up to six days and harvested at
days 1, 2, 4 or 6 of differentiation (D1, D2, D4 or D6).
2.4. Gene expression analysis
Total RNA was extracted using Tri-Reagent (Ambion Inc, Austin,
TX, USA), treated with DNAse I and RNase H (Life Technologies) and
quantitated using the NanoDrop 1000 spectrophotometer
(ThermoFisher Scientific, Scoresby, VIC, AUS). Half a microgram
of RNA was reverse-transcribed to form cDNA using the High
Capacity cDNA reverse transcription kit (Applied Biosystems,
Foster City, CA, USA) according to manufacturer’s instructions.
Semi-quantitative polymerase chain reaction (qPCR) was per-
formed using the Mx3000 PCR system (Stratagene, La Jolla, CA,
USA) with SYBR Green Master Mix (Applied Biosystems). The
cycling conditions included: 95 C for 10 min (1 cycle), 30 s at
95 C and 60 C for one min (40 cycles). Primers were synthesized
by GeneWorks (Adelaide, SA, AUS) and their sequences are listed in
Table 1. Samples were measured in triplicate and the relative gene
expression expressed as arbitrary units (A.U.) or fold-change,
which was calculated using 2DCt and normalized to 36B4 gene
expression (for proliferation) or cDNA input as determined by
Quant-iTTM OliGreen ssDNA Assay Kit (for differentiation) (Life
Technologies).
2.5. Western blotting
Cells were lysed in 1 modified RIPA buffer (50 mM Tris–HCl,
pH 7.4, 150 mM NaCl, 0.25% deoxycholic acid, 1% NP-40, 1 mM
EDTA) (Merck Millipore, North Ryde, NSW, AUS) containing dilu-
tion of 1:1000 protease inhibitor cocktail (Sigma–Aldrich) and
1:100 Halt phosphatase inhibitor cocktail (ThermoFisher
Scientific). Protein lysate concentrations were determined using
PierceTM BCA Protein Assay Kit (ThermoFisher Scientific). For
de-phosphorylation analysis, cells were harvested in 50 mM
Tris–HCl, pH 7.4, 150 mM NaCl, 0.25% deoxycholic acid, 1%
Triton-X100 and protease inhibitor cocktail. Following determina-
tion of protein concentration, lysates were treated with 1000 U
lambda phosphatase for 2 h at 30 C (New England Biolabs, MA,
USA). Thirty or sixty micrograms of protein lysates were elec-
trophoresed on either 12% or 8% SDS–PAGE gels and transferred
to Immobilon-FL polyvinylidene difluoride membrane (Merck
Millipore, Kilsyth, VIC, AUS). Membranes were blocked in 5%
BSA/Tris-Buffered saline with Tween-20 (TBST; 50 mM Tris,
150 mM NaCl, 0.1% Tween-20) for 1 h before incubation at 4 C
overnight in primary antibodies diluted in 5% BSA/TBST. Rabbit
polyclonal anti-cyclin B1 (#4138; 1:500), anti-p27 Kip1 (#2552;
1:300), anti-caspase 3 (#9662; 1:2500), anti-phospho Rb
(Ser780) (#3590; 1:500), anti-phospho Akt (Ser473) (#9271;Table 1
Primers used for qPCR analysis.
Gene ID GenBank accession No.
36B4 NM_007475.5
Ndrg2 NM_013864.2
p21/Cdkn1a NM_001111099.1
p27/Cdkn1b NM_009875.4
Ccnb1/Cyclin B1 NM_172301.3
Ccnd1/Cyclin D1 NM_007631.2
Cdk2 NM_183417.3
Myod1 NM_010866.2
Myogenin NM_031189.2
Myf5 NM_008656.5
Acta1 NM_001272041.1
Ckm NM_007710.2
Myh7 NM_080728.21:1000), anti-PARP (#9532; 1:300), rabbit monoclonal anti-Cdk2
(#2546; 1:250) and mouse monoclonal anti-cyclin D3 (#2936;
1:1000) were obtained from Cell Signaling (Beverly, MA, USA).
Rabbit polyclonal antibodies anti-Myf5 (sc-302; 1:200) and
anti-MyoD (sc-760; 1:350), and mouse monoclonal antibodies
anti-myogenin (sc-12732; 1:200) and anti-GRP78 (sc-376768;
1:200) were from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Mouse monoclonal antibodies, anti-myosin, type 1 slow
(M8421; 1:5000), anti-Bax (B9054; 1:100) and anti-FLAG (M2;
1:1000), and rabbit polyclonal anti-NDRG2 (HPA002896; 1:5000)
were obtained from Sigma–Aldrich. Mouse monoclonal antibodies,
anti-Bcl-2 (#610539; 1:100) and anti-Bcl-xL (#610747; 1:100)
were from BD Transduction Laboratories (BD Biosciences, San
Jose, CA, USA) and the rabbit polycolonal anti-Mcl-1 (1:8000)
was from Rockland Immunochemicals Inc. (Limerick, PA USA).
Rabbit monoclonal anti-p21 waf/cip1 (ab109199; 1:1000) and
mouse monoclonal antibodies, anti-a-tubulin (clone DM1A;
1:5000) and anti-b-Actin (ab6276; 1:10,000), were obtained from
Abcam (Cambridge, MA, USA). The detection of proteins was
performed using goat anti-rabbit AlexaFluor680 or donkey anti-
mouse AlexaFluor800 IgG antibodies (Life Technologies) diluted
at 1:10,000 in 50% Odyssey blocking buffer (Li-COR Biosciences,
Lincoln, NE, USA), 50% TBST and 0.01% SDS. Membranes were
imaged using the infrared imaging system (Li-COR Biosciences).
Proteins were normalized against heat shock protein 90 (HSP90),
a-tubulin or b-actin protein levels using the Li-COR software.
2.6. BrdU labeling assay
The proliferation rate of myoblasts was assessed using the col-
orimetric 5-bromo-20-deoxy-uridine (BrdU) Labeling and Detection
Kit III assay (Roche Applied Science, Indianapolis, IN, USA) accord-
ing to the manufacturer’s protocol. The BrdU label reagent was
added at a 1:90 dilution to the medium 16 h prior to analysis.
BrdU incorporation into the DNA was detected using horseradish
peroxidize conjugated BrdU antibodies and measured using a
Synergy 2 Multi-Mode microplate reader (BioTek, Winooski, VT,
USA) at 405 nm with a reference wavelength of 490 nm following
the addition of the peroxidase substrate, ABTS (2,20-azino-bis,
3-ethylbenzthiazoline-6-sulfonic acid).
2.7. Immunohistochemistry and fusion index
Cells were washed in PBS before being fixed in cold 4%
paraformaldehyde (PFA) (Sigma–Aldrich) in PBS for 20 min.
Following washing, cells were permeabilized in 0.5% Triton X-
100/PBS for 10 min, washed again and blocked overnight in 3%
BSA/PBS at 4 C. Cells were incubated in 1:1000 dilution of mouse
monoclonal anti-myosin, type 1 slow (M8421; Sigma–Aldrich) for
24 h at 4 C. Following washing, cells were incubated for 1 h withForward (50–30) Reverse (50–30)
ttgtgggagcagacaatgtg agtcctccttggtgaacacg
gagttagctgcccgcatcc gtgaccgagccataaggtgtc
gccttgtcgctgtcttgc cgcttggagtgatagaaatctgtc
gagcagtgtccagggatgagg tccacagtgccagcgttcg
agccatggcgctcagggtcac gggtcagccccatcatctgcg
gcccgaggagctgctgcaaa tcaggccttgcatcgcagcc
tacccagtactgccatccga ccggaagagttggtcaatct
ctggttcttcacgcccaaa ctggaagaacggcttcgaagg
tccatcgtggacagcatcac caatctcagttgggcatggttt
caccacaaccaaccctaacca actctcaatgtagcggattgca
gagcgtggctattccttcgt ctttgatgtcgcgcacaatc
cccacagacaagcataagac cccgtcaggctgttgagag
accctcaggtggctccgaga tgcagccccaaatgcagcca
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Technologies), washed again and incubated 15 min with
diamidino-2-phenylindole (DAPI) (1:1000; Sigma–Aldrich). Cells
were imaged using the Olympus IX70 fluorescent microscope
(Olympus, Notting Hill, VIC, AUS) at 10 magnification and 10
fields of view were imaged per condition. The fusion index of dif-
ferentiating myocytes was analyzed as described previously [31].
Fusion index was calculated as the number of myosin-positive cells
displaying at least three nuclei divided by the total number of
nuclei per field of view as determined using ImageJ software
(National Institutes of Health, Bethesda, MD, USA).
2.8. Caspase 3/7 assays
Caspase 3/7 activities were measured using Caspase-Glo 3/7
Assay (Promega, Annandale, NSW, AUS) according to manufac-
turer’s instructions. Briefly, cells were grown in white-walled 96-
well plates and the Caspase-Glo 3/7 reagent was added to the cells
(1:1) and control wells (growth media only). Incubation time was
optimized at 30 min and caspase 3/7 luminescence as relative light
units (RLU) was measured using the Synergy 2 Multi-Mode micro-
plate reader. The average background reading of control wells were
subtracted from all values and final values were normalized to pro-
tein content.
2.9. TUNEL analysis
Myoblasts were prepared using the APO-BrdU TUNEL Assay Kit
(Invitrogen) according to manufacturer’s instructions. Briefly, cells
were fixed in 1% PFA/PBS and placed on ice for 15 min. Cells were
washed in PBS and resuspended in 70% ethanol and stored
at 20 C. Cells were then labeled with BrdU 50-triphosphate and
terminal deoxynucleotidyl transferase at room temperature over-
night with gentle agitation. Cells were washed and the Alexa
Fluor 488 dye-labeled anti-BrdU antibodywas added and incubated
for 30 min away from light. Cells were then diluted in PBS and
imaged using the Olympus IX70 fluorescent microscope. Ten fields
of view were analyzed per condition. The number of apoptotic cells
were counted and divided by the total number of cells per field of
view using ImageJ software (National Institutes of Health).
2.10. Apoptotic DNA laddering
Genomic DNA was extracted from cells using a Genomic DNA
Extraction kit (Life Technologies). DNA concentrations were deter-
mined using the NanoDrop 1000 spectrophotometer (ThermoFisher
Scientific). An apoptotic positive control (lyophilized apoptotic
U937 cells; Roche, Basel, Switzerland) and 2 lg of each DNA sample
were electrophoresed on a 1% agarose-Tris–acetate–EDTA gel. Gel
images were obtained using the Gel DocTM XR+ (Bio-Rad, Hercules,
CA, USA).
2.11. Statistics
Data presented as the mean ± S.E.M. Statistical significance was
determined using one-way ANOVA with Bonferroni post hoc com-
parisons using GraphPad Prism 6 (GraphPad Software, La Jolla,
CA, USA). A P-value of <0.05 was considered statistically
significant.
3. Results
Initially, the expression levels of NDRG2 and 3A-NDRG2 follow-
ing their overexpression were established in both proliferating and
differentiated myoblasts. NDRG2 and 3A-NDRG2 mRNA levelsincreased approximately 250-fold in myoblasts at day 3 of prolifer-
ation (P3) (P < 0.001) and 90-fold at day 6 of differentiation (D6) in
myotubes (P < 0.001) when compared to endogenous NDRG2 gene
expression represented by the vector control (Fig. 1A). Accordingly,
NDRG2 and 3A-NDRG2 overexpression increased their respective
protein levels significantly above endogenous NDRG2 protein
expression (Fig. 1B), which increases with C2C12 myoblast differ-
entiation as previously reported [15]. However, overexpressed
NDRG2 protein remained 2-fold higher than 3A-NDRG2 protein
levels at each stage of proliferation and differentiation (P < 0.05;
Fig. 1B). To address if there was a difference in protein stability,
the half-life of the overexpressed NDRG2 and 3A-NDRG2 proteins
tagged with a FLAG epitope were measured. The half-life of
NDRG2 protein was reported previously as less than 8 h in pancre-
atic beta-cells [18]. Here, however, we found that both NDRG2 and
3A-NDRG2 displayed a half-life of more than 12 h and were both
essentially degraded by 24 h suggesting similar stabilities
(Fig. 1C). The short-lived pro-survival protein, myeloid cell leuke-
mia 1 (Mcl-1), had also decayed by 4 h as expected [32].
Moreover, detection of the two NDRG2 proteins with the FLAG
antibody revealed comparable levels of expression. Finally, treat-
ment of the protein lysates with lambda protein phosphatase, a
Ser, Thr and tyrosine phosphatase, revealed equivalent levels of
de-phosphorylated NDRG2 protein expression in both NDRG2
and 3A-NDRG2 compared with untreated samples (Fig. 1D).
Phospho-Akt levels were also measured to confirm the de-
phosphorylation effect of the phosphatase. Therefore, we attribute
the difference between the overexpressed NDRG2 and 3A-NDRG2
protein levels to greater reactivity displayed by the NDRG2-
specific antibody for the phosphorylated form of NDRG2, compared
to 3A-NDRG2, rather than a stability difference between the two
proteins.
Having established comparable overexpression levels between
NDRG2 and 3A-NDRG2, C2C12 myoblast proliferation rates were
assessed at P2 and P3. To note, in this study, our aim was not to
compare between time-points, but rather to focus on the effect
of the NDRG2 proteins at each given time-point. At P2, NDRG2
increased proliferation 1.25-fold (P < 0.001) when compared with
the vector. There was no effect of 3A-NDRG2 on proliferation. At
P3, both NDRG2 and 3A-NDRG2 increased proliferation by 1.4-
fold (P < 0.001) and 1.2-fold (P < 0.05), respectively (Fig. 2A). The
increase in proliferation with NDRG2 overexpression remained
higher than the effect of 3A-NDRG2 (P < 0.05). NDRG2 or 3A-
NDRG2 did not affect cyclin E, Cdk4 or Cdk6 protein levels
(Fig. 2B) at P3. However, NDRG2 increased both the mRNA and pro-
tein expression of the positive cell cycle regulators Cdk2
(P < 0.001), cyclin B (P < 0.01) and cyclin D (P < 0.05; Fig. 2C).
Similarly, 3A-NDRG2 increased the levels of Cdk2 mRNA and pro-
tein, and cyclin B mRNA (P < 0.05). The phosphorylated levels of
Rb also increased significantly following NDRG2 overexpression
above both vector and 3A-NDRG2 (P < 0.05; Fig. 2D) indicating
increased inhibition of Rb and enhanced cell cycle progression.
The expression of the cell cycle inhibitors p27 Kip1 (p27) and
p21 were also investigated. Following NDRG2 overexpression p27
mRNA levels were reduced 1.4-fold (P < 0.05) at P2 with a corre-
sponding 2-fold suppression of its protein levels at P3 (P < 0.05,
Fig. 3A). In contrast, no difference in p21 mRNA was observed at
P2 or P3. However, when myoblasts reached confluence (D0),
p21 mRNA and protein levels increased 1.7-fold with NDRG2 treat-
ment (P < 0.001; Fig. 3B). No effect of 3A-NDRG2 was observed for
any of the mRNA or protein targets measured.
The effects of NDRG2 and 3A-NDRG2 overexpression during the
early stages of differentiation were next investigated through the
expression analyses of the MRFs, Myf5, MyoD and myogenin.
NDRG2 overexpression increased Myf5 mRNA and protein expres-
sion by 1.5- and 1.3-fold at P3 and D0, respectively, while mRNA
αα
Fig. 1. NDRG2 and 3A-NDRG2 overexpression characterization. NDRG2 mRNA (A) and protein (B) expression levels following infection with empty vector (black bars; V),
NDRG2 (white bars; N) or 3A-NDRG2 (gray bars; 3A) at day 3 of proliferation (P3) and day 6 of differentiation (D6) (n = 3 per treatment). b-Actin expression indicates protein
levels loaded. ***P < 0.001 and *P < 0.05 compared to vector; #P < 0.05 and ##P < 0.01 compared to NDRG2. (C) Immunoblots representing a time-course (h) of FLAG-NDRG2 (F-
N) and FLAG-3A-NDRG2 (F-3A) protein stability following 10 lg/ml cycloheximide (CHX) treatment. An untransfected control (UT) is included and FLAG, Mcl-1 and a-tubulin
protein levels are indicated. (D) Phosphorylated and de-phosphorylated levels of NDRG2, a-tubulin and phospho-Akt proteins in untreated ( phosphatase) and lambda
protein phosphatase-treated (+ phosphatase) protein lysates following infection with vector (V), NDRG2 (N) or 3A-NDRG2 (3A) at P3. Normalized to a-tubulin protein, fold-
change of NDRG2 expression to vector controls is indicated.
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while 3A-NDRG2 increased Myf5 protein levels at P3 (P < 0.05;
Fig. 4A). For MyoD expression levels, NDRG2 overexpression
increased mRNA expression by 1.2-fold at P3 and D0, and protein
levels by 1.7-fold at D0 (P < 0.05; Fig. 4B). No difference in MyoDmRNA or protein expression was observed at D1 and no effect by
3A-NDRG2 was found. Finally, myogenin levels were examined
over the course of differentiation and NDRG2 overexpression
increased myogenin mRNA and protein expression by 4.4-fold at
P3 (P < 0.05) as well as increasing myogenin protein expression
Fig. 2. The effect of NDRG2 and 3A-NDRG2 overexpression on C2C12 myoblast proliferation and expression of positive cell cycle regulators at day 2 (P2) or day 3 (P3) of
proliferation. (A) Proliferation rate of C2C12 myoblasts following infection with vector (black bars), NDRG2 (white bars) or 3A-NDRG2 (gray bars) (n = 6 per treatment) at P2
and P3. (B) Protein expression of cell cycle regulators cyclin E, Cdk4 and Cdk6. (C) mRNA (upper panel) and protein (lower panel) expression of Cdk2, cyclin B, cyclin D, and
(D), Rb phosphorylation levels following vector, NDRG2 and 3A-NDRG2 overexpression at P3. Data are mean of three independent experiments (n = 3 per treatment). HSP90
or b-actin expression indicates protein levels loaded. ***P < 0.001, **P < 0.01, *P < 0.05 compared to vector; ###P < 0.001, ##P < 0.01 and #P < 0.05 compared to NDRG2.
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when maximal myogenin expression was reached (P < 0.05;
Fig. 4C). No difference in myogenin mRNA or protein expression
was observed at D1 or with 3A-NDRG2 overexpression.
Myocyte fusion was next assessed by measuring the number of
nuclei in differentiating myocytes as identified through theirexpression of myosin, type 1 slow (myosin, heavy polypeptide 7;
MYH7) protein at D2. MYH7-positive myocytes with more than
three nuclei per myocyte were counted in the analyses (Fig. 5A).
When compared to the vector control and 3A-NDRG2, NDRG2
overexpression increased the fusion index by 46% (P < 0.01) and
38% (P < 0.05), respectively (Fig. 5B). 3A-NDRG2 did not
Fig. 3. The expression of negative cell cycle regulators following NDRG2 and 3A-NDRG2 overexpression in myoblasts at days 2 and 3 of proliferation (P2 and P3) and at
confluence (D0). (A) p27 mRNA (upper panel) and protein (lower panel) expression, and (B) p21 mRNA (upper panel) and protein (lower panel) expression with
representative blots indicated. Data are mean of three independent experiments (n = 3 per treatment). HSP90 expression indicates protein levels loaded. ***P < 0.001 and
*P < 0.05 compared to vector; ###P < 0.001 compared to NDRG2.
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tein were then measured at D2, D4 and D6 with NDRG2 signifi-
cantly increasing expression at D2 and D4 but not at D6
(Fig. 5C and D) when cells are well differentiated (Fig. 5G). 3A-
NDRG2 also increased Myh7 mRNA and MYH7 protein expression
at D4. No difference, however, was measured between treatments
on any day for markers of differentiated muscle cells [33,34]
including muscle creatine kinase (Ckm) and skeletal musclealpha-actin (Acta1) (Fig. 5E and F) and no clear phenotypic differ-
ences in the differentiated myotubes were evident at D6 between
treatments (Fig. 5G).
To determine whether increased expression of NDRG2 pro-
moted apoptosis in C2C12 myoblasts during normal growth condi-
tions, indices of apoptosis were measured in the proliferating and
differentiating cells. Initially, the activities of caspases 3/7, effector
caspases of apoptosis initiation, were investigated. NDRG2
Fig. 4. NDRG2 and 3A-NDRG2 overexpression effect on MRFs expression levels. (A) Myf5, (B) MyoD and (C) Myogenin mRNA (upper panels) and protein (lower panels)
expression levels with representative blots indicated in C2C12 cells at P3, D0, D1 and up to D6 for myogenin. Myoblasts are infected with vector alone (black bars), NDRG2
(white bars) and 3A-NDRG2 (gray bars). All data are averages of three independent experiments (n = 3 per condition). ***P < 0.001, **P < 0.01 and *P < 0.05 compared to vector;
##P < 0.01, #P < 0.05 compared to NDRG2.
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1.7-fold at P2, P3 and D0, respectively (P < 0.001 at P3 and D0;
Fig. 6A), whereas 3A-NDRG2 had no effect. However, no difference
in the number of TUNEL positive cells was observed at P3 (Fig. 6B).
Additionally, no increase in apoptotic DNA laddering at P3 (Fig. 6C)
or during D1–2 (data not shown) was found with any of the treat-
ments. Furthermore, the protein levels of cleaved poly (ADP ribose)
polymerase (PARP) and cleaved caspase 3 proteins at P3 (Fig. 6D)
and during D0–2 (data not shown) were not altered. The anti-
apoptotic regulators Bcl-2 and Bcl-2-like 1 (Bcl-xL), as well as the
pro-apoptotic protein Bax remained unchanged at P3 (Fig. 6D).
However, at D0 the protein expression of Bax and Bcl-xL were both
decreased by 1.4-fold following NDRG2 overexpression (P < 0.01;Fig. 6E). 3A-NDRG2 also decreased Bcl-xL protein expression by
1.5-fold (P < 0.01), but had no effect on Bax expression.
We next assessed the role for NDRG2 and 3A-NDRG2 under dif-
ferent stress treatments during myoblast proliferation. Both PA and
H2O2 treatments cause significant apoptosis with oxidative and ER
stress observed in C2C12 muscle cells [21–23,35]. Accordingly, we
determined that 0.5 mM PA and 0.5 mM H2O2 treatments reduced
myoblasts proliferation by nearly 50% after 16 and 8 h treatments,
respectively (P < 0.001), while shorter exposure times also signifi-
cantly decreased proliferation (P < 0.05; Table 2). Both NDRG2
and 3A-NDRG2 overexpression were unable to alter the prolifera-
tion rates of the myoblasts in the presence of PA treatment
(Table 2). Nor did they alter the protein levels of apoptosis or ER
Fig. 5. NDRG2 and 3A-NDRG2 overexpression effect on myocyte fusion index and gene markers of differentiation. (A) Fusion index (n = 10 fields of view per condition)
following vector (V), NDRG2 (N) and 3A-NDRG2 (3A) overexpression. (B) Immunofluorescent images of differentiating C2C12 myocytes at D2. Nuclei are stained with DAPI
(blue labeling) and fusing myocytes are stained for MYH7 expression (red labeling). Scale bar = 200 lM. (C) mRNA and (D) protein expression levels of Myh7, and mRNA levels
of (E) Ckm and (F) Acta1 at D2, D4 and D6 (n = 3 per condition). (G) Phenotypic appearance of C2C12 myotubes at D6 following vector, NDRG2 and 3A-NDRG2 overexpression.
Scale bar = 50 lM. ***P < 0.001, **P < 0.01 and *P < 0.05 compared to vector; ###P < 0.001, #P < 0.05 compared to NDRG2.
676 K.J. Anderson et al. / FEBS Open Bio 5 (2015) 668–681stress markers including PARP and caspase 3 cleavage, Bcl-2 family
members Bcl-2, Bcl-xL, Bax and Mcl-1, and glucose-regulated pro-
tein 78 (GRP78) (Fig. 7). In contrast, NDRG2 overexpression inhib-
ited the decrease in cell proliferation following 4 h H2O2 treatment
and attenuated the effect of H2O2 at 8 h with only a 17% prolifera-
tion decrease measured (P < 0.05) when compared to the 48%
decrease with the vector alone (P < 0.001; Table 2). Moreover,
NDRG2 reduced the amount of PARP and caspase 3 cleavage at
8 h (Fig. 8A and B) and reduced the loss of Bcl-2 and Bcl-xL
(Fig. 8C and D) but Mcl-1 expression did not change (Fig. 8E).The induction of both Bax and GRP78 expression levels by H2O2
treatment was blocked by NDRG2 at 4 and 8 h time-points
(Fig. 8F and G). 3A-NDRG2 only had moderate effects in preventing
the loss in cell proliferation following H2O2 treatment (Table 2) and
in regulating the expression of the apoptotic and ER stress protein
markers (Fig. 8). Interestingly, both endogenous and overexpressed
NDRG2 protein levels were significantly reduced by 8 h of H2O2
exposure with 80%, 50% and 60% decrease in NDRG2 expression
measured in vector, NDRG2- and 3A-NDRG2-treated myoblasts,
respectively (Fig. 8H).
Fig. 6. Caspase 3/7 activities and apoptosis levels in proliferating and differentiating C2C12 myoblasts following NDRG2 and 3A-NDRG2 overexpression. (A) Caspase 3/7
activities in myoblasts at P2, P3 and D0. Cells were infected with vector alone (black bars), NDRG2 (white bars) or 3A-NDRG2 (gray bars). Luminescence as a reflection of
activity is represented as relative light units (RLU), n = 6 per sample. (B) Percentage of TUNEL positive myoblasts (10 fields of view counted per treatment), and (C) apoptotic
DNA laddering gel at P3. Lanes: L, DNA 1 kb ladder; +C, positive control apoptotic U937 cells; V, vector; N, NDRG2; and 3A, 3A-NDRG2. (D) Immunoblots of total and cleaved
PARP, total and cleaved caspase 3, Bcl-2, Bcl-xL and Bax proteins at P3, and (E), at or D0 for Bcl-2, Bcl-xL and Bax proteins (n = 3 per treatment). b-Actin protein indicates
protein levels loaded. Data are mean of three independent experiments. ***P < 0.001 and **P < 0.01 compared to vector; ###P < 0.001 and #P < 0.05 compared to NDRG2.
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This study aimed to investigate the effect of NDRG2 on myo-
genic processes and apoptosis under both normal growth and
stress-induced conditions in C2C12muscle cells. We identified thatincreased levels of NDRG2 promoted the proliferation, and hence,
onset of differentiation of C2C12 myoblasts although the overall
level of differentiation in mature myotubes was not different. In
addition, NDRG2 overexpression attenuated the stress induced by
H2O2 treatment while a phospho-deficient form of NDRG2
Table 2
The % decrease in myoblast proliferation at P3 following vector, NDRG2 and 3A-
NDRG2 overexpression and 0.5 mM PA or 0.5 mM H2O2 treatments.
PA Vector NDRG2 3A-NDRG2
0 h 0% 0% 0%
8 h ; 32%** ; 30%** ; 29%*
16 h ; 44%*** ; 49%*** ; 44%***
H2O2
0 h 0% 0% 0%
4 h ; 23%* ; 3% ; 15%*
8 h ; 48%*** ; 17%* ; 36%***
* P < 0.05.
** P < 0.01.
*** P < 0.001 to each 0 h control group; n = 6 per treatment.
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observations identifying that the knockdown of NDRG2 impaired
myogenesis in vitro [15] and corroborate a unique role for
NDRG2 in myoblast growth and response to stress in skeletal mus-
cle cells.
Here, we demonstrated that NDRG2 enhanced the expression of
the positive cell cycle proteins Cdk2, cyclin B and cyclin D and
down-regulated the negative cell cycle regulator p27 during prolif-
eration. In addition, increased phosphorylation of the tumor sup-
pressor Rb protein was measured, most likely due to enhanced
activity of cyclins and Cdks (reviewed in [3]). This was followed
by the up-regulation of p21 at myoblast confluence corresponding
to cell cycle exiting and commitment to differentiation [5,36].
Cyclins A and B target the phases of growth (G2) and mitosis (M)
phases, whereas Cdk2 complexes with cyclins A and E acting on
the later G1 and synthesis phases, and cyclin D targets the resting
G0 to early G1 phase (reviewed in [37]). Therefore, it appears that
NDRG2 overexpression generates a positive broad cell-cycle effect
in C2C12 myoblasts rather than targeting a single, specific phase of
the cell cycle. Indeed, a recent study that overexpressed NDRG2 in
proliferating C2C12 myoblasts found that NDRG2 had no specific
effect on any particular phase of the cell cycle [38]. However, this
study also reported that NDRG2 overexpression increased the pool
of dividing myoblasts and the G2/M phase with less cells in the G1/
G0 resting phase within 24 h of adding differentiation media to theFig. 7. Protein expression levels of NDRG2, apoptotic and ER stress markers
following 0, 8 and 16 h palmitate (PA) treatment of vector, NDRG2 and 3A-NDRG2-
infected C2C12 myoblasts at P3. Protein loading is indicated by the a-Tubulin
immunoblots.myoblasts [38]. The authors interpreted this as a delay in cell cycle
withdrawal during differentiation, which may equate to increased
proliferation but this was not measured under these conditions. In
contrast, we did not observe any delay in cell cycle exiting with our
myoblasts in growth medium. We observed both a higher prolifer-
ation rate and significantly elevated p21, MyoD and myogenic
expression levels from NDRG2 overexpression at D0 indicating cell
cycle exiting and commitment to differentiate earlier than myo-
blasts infected with vector alone or with 3A-NDRG2 overexpres-
sion. While a higher myocyte fusion index was measured at D2,
the overall level of differentiation was not greater by D6 suggesting
that NDRG2 primarily affected myoblast proliferation. The broad
effects of NDRG2 on cell cycle control are further highlighted in
reports in cancer cells. NDRG2 overexpression down-regulated
cyclin D1 in human colon carcinoma cells [29] whereas it sup-
pressed cyclin E, but not cyclin D or Cdk2, resulting in cell cycle
arrest at the G1/S phase in rat liver cells [39]. Similarly to our find-
ings here, a Ser/Thr phospho-deficient form of human NDRG2 did
not significantly alter cyclin D or p21 expression levels in the colon
carcinoma cells. This NDRG2 mutant also displayed a reduced inhi-
bitory effect on cancer growth [29] compared with human NDRG2
overexpression suggesting that the specific Ser and Thr residues in
both the human and mouse NDRG2 protein contribute to its activ-
ity in cancer and muscle cells. How NDRG2 affects cellular prolifer-
ation and why changes in NDRG2 expression have opposing effects
on cell proliferation in C2C12 myoblasts compared with human
cancer cells are currently unknown. It is interesting to note that
the knockdown of the ortholog NDRG4 reduces cardiac myocyte
proliferation [40] despite being described as a tumor suppressor
while NDRG3 appears to play a more cancer growth-promoting
role [41]. Clearly, further investigation into the mechanisms of
how the NDRG proteins control cell growth in cancer versus non-
cancer cells is warranted.
While NDRG2 has been described to enhance apoptosis in non-
cancer [39,42] and cancer [43,44] cell types, we did not observe an
increase in myoblast apoptosis under basal growth conditions in
C2C12 myoblasts nor change in Bcl-2 levels unlike the decreased
Bcl-2 expression reported in Hela cells following NDRG2 overex-
pression [19]. A decrease in the expression of both the anti-
apoptotic Bcl-xL and the pro-apoptotic Bcl-2 family member Bax
were measured following overexpression NDRG2 but are in con-
trast to the increased Bax expression observed in liver cells [39].
The significance of reduced Bax and Bcl-xL levels in muscle cells
is unknown although overexpression of Bcl-xL can inhibit myotube
formation [9]. Indeed, non-apoptotic roles for the Bcl-2 family are
being realized including regulation of calcium homeostasis and ER
function [45]. The role of caspase 3 in muscle cell differentiation is
not entirely clear at present. Enhanced activities of caspase 3, and
potentially its upstream initiator, caspase 9, are required for myo-
blast fusion and differentiation [8,9,46,47]. In C2C12 myoblasts,
caspase 3 activation along with transient activation of caspase 2
in differentiating myoblasts were measured although caspase 8
or 9 activities were not increased [48]. Interestingly, this study also
determined that neither X-linked inhibitor of apoptosis protein nor
mitochondrial-based apoptosis were involved in the transient cas-
pase 3 activation measured [48]. Indeed, increased caspase 3 has
been linked to the cleavage of actomyosin and ubiquitin–protea-
some muscle proteolysis [49] and instead may be required for
organelle remodeling during normal cell function [50]. Caspase 3
is also thought to contribute to myogenesis through the regulation
of mechanosensitive cation channels [46] and through an effector
molecule, the Mammalian Sterile Twenty-like kinase [8].
During H2O2-induced stress conditions, we observed that
NDRG2 helped attenuate a loss in cell proliferation and the induc-
tion of apoptosis. This was in parallel with a reduced loss in the
pro-survival factors Bcl-2 and Bcl-xL, but not Mcl-1, suggesting
Fig. 8. Protein expression levels of apoptotic and ER stress markers following H2O2 treatment of vector, NDRG2 and 3A-NDRG2-infected C2C12 myoblasts at P3. Protein
expression levels of (A) total and cleaved PARP, (B) total and cleaved caspase 3, (C) Bcl-2, (D) Bcl-xL, (E) Mcl-1, (F) Bax, (G) GRP78 and (H) NDRG2 proteins. Alpha-tubulin (a-
Tubulin) protein indicates protein levels loaded. Hydrogen peroxide treatment times were 0 h (black bars), 4 h (white bars) or 8 h (gray bars). Data are the mean of three
independent experiments (n = 3 per treatment). ***P < 0.001, **P < 0.01 and *P < 0.05 compared to each 0 h control.
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ever, decreased levels of endogenous and exogenous NDRG2 were
observed also with the induced stress. The cause of this loss in
NDRG2 is not known currently but NDRG2 may be a target for
ubiquitin-mediated degradation during stress as NDRG2 has been
reported a substrate of the E3 Ligase Trim32 ubiquitination in
skeletal muscle [38]. Indeed, Cyclin D1 is a targeted for
ubiquitin-dependent proteasomal degradation during oxidative
stress mediated by H2O2 exposure [51]. Interestingly, no protectiveeffect was identified during PA treatment despite H2O2 and PA
treatments inducing both oxidative and ER stress and apoptosis
[21–23,35]. A potential explanation for this difference may lie
within the regulation of NDRG2’s C-terminal amino acids, Ser332,
Thr348 and Ser350. Our data confirm that the phosphorylation status
is important for NDRG2 function as the removal of these residues
did ablate the NDRG2 increase in caspase 3/7 activities, myocyte
fusion and protection against H2O2 treatment. Whether Ser332,
Thr348 and Ser350 contribute significantly individually or in
680 K.J. Anderson et al. / FEBS Open Bio 5 (2015) 668–681combination to the function of mouse NDRG2 is yet to be deter-
mined. The Ser/Thr kinases that potentially target these residues
in skeletal muscle include Akt, PKCh and serum- and
glucocorticoid-inducible kinase 1 (SGK1) [24,25]. The possible
impact of Akt and SGK1 on NDRG2 phosphorylation and regulation
in the context of myoblast proliferation and differentiation, partic-
ularly by Akt1 and Akt2, has been discussed previously [15]. The
role for PKCh in muscle growth and homeostasis is less clear.
While PKCh promotes myoblast fusion [27], reduced levels of
PKCh appear to enhance myogenesis [28] and ameliorate muscle
dystrophy [52]. Of particular interest to this study here is the
potential inhibitory regulation of NDRG2 by PKCh [24], which itself
becomes activated upon PA treatment in C2C12 cells [53,54]. As
PKCh phosphorylates Ser332 in the mouse NDRG2 protein sequence,
it has been shown it can block phosphorylation of the Thr348 site by
insulin [24]. Potentially, this inhibition of Thr348 phosphorylation
during PA treatment, and presumably PKCh activation, may pre-
vent NDRG2’s protective function and provide an explanation for
NDRG2’s inability to attenuate lipotoxicity in C2C12 muscle cells.
The positive effects of Akt and insulin on NDRG2 function are high-
lighted where the knocked down of NDRG2 removed the ability of
a constitutively active Akt to block apoptosis induced by PA in pan-
creatic beta cells [18]. Whether NDRG2 overexpression alone could
protect against lipotoxicity in the pancreatic beta cells was not
reported.
In conclusion, this study demonstrates that in C2C12 myoblasts
NDRG2 promotes their proliferation and earlier onset of myogenic
differentiation, which may be contributed to by at least one of its
Ser332, Thr348 or Ser350 phosphorylation sites. Furthermore the
pro-myogenic role of NDRG2 was elicited partially through
enhanced caspase 3/7 activities. NDRG2 overexpression attenuated
oxidative and ER stress and apoptosis induced by treatment with
H2O2, but not from PA-induced lipotoxicity. Confirmation of these
findings in vivo and the amino acid residues specifically targeted by
Ser/Thr kinases during skeletal muscle development and under dif-
ferent stress conditions remain to be determined. Such studies will
further enhance our understanding of the physiological role and
regulation of NDRG2 in skeletal muscle.
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